依奇珠单抗治疗中重度斑块状银屑病的药物经济学评价(4)
[13] JOHANSSON EC，HARTZ S，KIRI SH，et al. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK[J]. J Med Econ，2018，21(8)：810-820.
[14] RAMAEKERS BLT，WOLFF RF，POUWELS X，et al. Ixekizumab for treating moderate-to-severe plaque psoriasis：an evidence review group perspective of a NICE single technology appraisal[J]. Pharmacoeconomics，2018，36(8)：917-927.
[15] Eli Lilly and Company Limited. Ixekizumab for the treatment of moderate to severe plaque psoriasis [ID：904]：company submission to national institute of health and care excellence (Version1.0)[EB/OL].(2016-11)[2019- 11-01].https：//www.nice.org.uk/guidance/ta442/documen- ts/committee-papers-3.
[16] WOLFF R，JOORE M，POUWELS X，et al. Ixekizumab for treating moderate to severe chronic plaque psoriasis：a single technology appraisal[EB/OL].(2017-10-03)[2019-11-01].https：//www.nice.org.uk/guidance/ta442/documents/committee-papers-3.
(收稿日期：2019-11-14 修回日期：2020-01-13)
(編辑：邹丽娟), 百拇医药(刘国强 康朔)
[14] RAMAEKERS BLT，WOLFF RF，POUWELS X，et al. Ixekizumab for treating moderate-to-severe plaque psoriasis：an evidence review group perspective of a NICE single technology appraisal[J]. Pharmacoeconomics，2018，36(8)：917-927.
[15] Eli Lilly and Company Limited. Ixekizumab for the treatment of moderate to severe plaque psoriasis [ID：904]：company submission to national institute of health and care excellence (Version1.0)[EB/OL].(2016-11)[2019- 11-01].https：//www.nice.org.uk/guidance/ta442/documen- ts/committee-papers-3.
[16] WOLFF R，JOORE M，POUWELS X，et al. Ixekizumab for treating moderate to severe chronic plaque psoriasis：a single technology appraisal[EB/OL].(2017-10-03)[2019-11-01].https：//www.nice.org.uk/guidance/ta442/documents/committee-papers-3.
(收稿日期：2019-11-14 修回日期：2020-01-13)
(編辑：邹丽娟), 百拇医药(刘国强 康朔)